INTERVENTION 1:	Intervention	0
Arm I	Intervention	1
Observation (+/- Radiation). Patients receive radiotherapy* within 6 months after surgery.	Intervention	2
radiotherapy	OAE:0000235	46-58
surgery	OAE:0000067	82-89
radiation therapy: Given within 6 months after surgery	Intervention	3
surgery	OAE:0000067	47-54
INTERVENTION 2:	Intervention	4
Arm II	Intervention	5
Chemotherapy (+/- Radiation). Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.	Intervention	6
surgery	OAE:0000067	52-59
surgery	OAE:0000067	224-231
adjuvant	CHEBI:60809	103-111
radiotherapy	OAE:0000235	189-201
chemotherapy: Given within 10 weeks after surgery.	Intervention	7
surgery	OAE:0000067	42-49
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically confirmed invasive breast cancer	Eligibility	1
breast cancer	DOID:1612	34-47
First local and/or regional (i.e., ipsilateral axillary or internal mammary lymph node region) recurrence after primary treatment with mastectomy or lumpectomy/quadrantectomy with clear surgical margins	Eligibility	2
lymph	UBERON:0002391	76-81
Local failure is defined as a tumor recurrence in any soft tissue of the ipsilateral conserved breast or the chest wall, mastectomy scar, and/or skin	Eligibility	3
tissue	UBERON:0000479	59-65
breast	UBERON:0000310	95-101
chest	UBERON:0001443	109-114
Regional failure is defined as a tumor recurrence in the ipsilateral axillary lymph nodes, extranodal soft tissue of the ipsilateral axilla, and/or ipsilateral internal mammary. Regional failure does not include supraclavicular lymph nodes or tumor in the opposite breast	Eligibility	4
lymph	UBERON:0002391	78-83
lymph	UBERON:0002391	228-233
tissue	UBERON:0000479	107-113
breast	UBERON:0000310	265-271
No other prior recurrence in any site, including local	Eligibility	5
site	BFO:0000029	33-37
Surgical resection of the recurrence meeting 1 of the following criteria:	Eligibility	6
Uninvolved ("clear") margins and planned radiotherapy with at least 40 Gy for patients who had no prior adjuvant radiotherapy	Eligibility	7
radiotherapy	OAE:0000235	41-53
radiotherapy	OAE:0000235	113-125
adjuvant	CHEBI:60809	104-112
Mastectomy of the recurrence with uninvolved ("clear") margins after lumpectomy/quadrantectomy alone for the primary	Eligibility	8
Adjuvant trastuzumab (HerceptinÂ®) therapy or other HER-2 directed therapies are allowed for patients with HER-2 positive tumors and must be declared prior to randomization	Eligibility	9
adjuvant	CHEBI:60809	0-8
No evidence of distant metastasis, including ipsilateral supraclavicular lymph nodes, by x-ray or CT scan of the chest, ultrasound or CT scan of the abdomen and pelvis, or bone scintigraphy only if alkaline phosphatase is > 2 times normal or if medically indicated (e.g., bone pain)	Eligibility	10
lymph	UBERON:0002391	73-78
ct	BAO:0002125	98-100
ct	BAO:0002125	134-136
chest	UBERON:0001443	113-118
abdomen	UBERON:0000916	149-156
phosphatase	GO:0016791,BAO:0000295	207-218
bone pain	HP:0002653	272-281
No macroscopically incomplete surgery	Eligibility	11
surgery	OAE:0000067	30-37
No bilateral malignancy except carcinoma in situ	Eligibility	12
bilateral	HP:0012832	3-12
carcinoma	HP:0030731,DOID:305	31-40
No suspicious mass in the opposite breast unless that mass has been proven by biopsy to be benign	Eligibility	13
breast	UBERON:0000310	35-41
No skeletal pain of unknown cause	Eligibility	14
pain	HP:0012531	12-16
No hot spots on bone scan for which metastases cannot be ruled out by x-ray, MRI, and/or CT scan	Eligibility	15
ct	BAO:0002125	89-91
Hormone receptor status:	Eligibility	16
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Determined in the recurrent tumor by immunohistochemistry and/or ligand-binding assay	Eligibility	17
recurrent	HP:0031796	18-27
immunohistochemistry	BAO:0000415	37-57
Estrogen receptor positive or negative	Eligibility	18
estrogen	CHEBI:50114,BAO:0000760	0-8
receptor	BAO:0000281	9-17
Progesterone receptor positive or negative	Eligibility	19
progesterone	CHEBI:17026	0-12
receptor	BAO:0000281	13-21
PATIENT CHARACTERISTICS:	Eligibility	20
patient	HADO:0000008,OAE:0001817	0-7
Age	Eligibility	21
age	PATO:0000011	0-3
Minimum 18 years	Eligibility	22
Sex	Eligibility	23
Female	Eligibility	24
female	PATO:0000383	0-6
Menopausal status	Eligibility	25
Not specified	Eligibility	26
Performance status	Eligibility	27
Not specified	Eligibility	28
Life expectancy	Eligibility	29
Not specified	Eligibility	30
Hematopoietic	Eligibility	31
Not specified	Eligibility	32
Hepatic	Eligibility	33
No elevated alkaline phosphatase	Eligibility	34
phosphatase	GO:0016791,BAO:0000295	21-32
Renal	Eligibility	35
Not specified	Eligibility	36
Other	Eligibility	37
Fertile patients must use effective non-hormonal contraception	Eligibility	38
Medically suitable for chemotherapy of 3-6 months duration	Eligibility	39
duration	PATO:0001309	50-58
No other primary malignant tumors except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer	Eligibility	40
carcinoma	HP:0030731,DOID:305	60-69
skin cancer	DOID:4159	107-118
No non-malignant systemic disease that would preclude study treatment or prolong follow-up	Eligibility	41
disease	DOID:4,OGMS:0000031	26-33
No psychiatric or addictive disorder that would preclude giving informed consent	Eligibility	42
disorder	OGMS:0000045	28-36
No history of noncompliance to medical regimens or potential for being unreliable	Eligibility	43
history	BFO:0000182	3-10
PRIOR CONCURRENT THERAPY:	Eligibility	44
Biologic therapy	Eligibility	45
Not specified	Eligibility	46
Chemotherapy	Eligibility	47
See Disease Characteristics	Eligibility	48
disease	DOID:4,OGMS:0000031	4-11
Endocrine therapy	Eligibility	49
Not specified	Eligibility	50
Radiotherapy	Eligibility	51
radiotherapy	OAE:0000235	0-12
See Disease Characteristics	Eligibility	52
disease	DOID:4,OGMS:0000031	4-11
Surgery	Eligibility	53
surgery	OAE:0000067	0-7
See Disease Characteristics	Eligibility	54
disease	DOID:4,OGMS:0000031	4-11
Outcome Measurement:	Results	0
Disease-free Survival	Results	1
[Not Specified]	Results	2
Time frame: 5 years after randomization	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Arm I	Results	5
Arm/Group Description: Observation (+/- Radiation). Patients receive radiotherapy* within 6 months after surgery.	Results	6
radiotherapy	OAE:0000235	69-81
surgery	OAE:0000067	105-112
radiation therapy: Given within 6 months after surgery	Results	7
surgery	OAE:0000067	47-54
Overall Number of Participants Analyzed: 77	Results	8
Measure Type: Number	Results	9
Unit of Measure: percentage of participants  57        (44 to 67)	Results	10
Results 2:	Results	11
Arm/Group Title: Arm II	Results	12
Arm/Group Description: Chemotherapy (+/- Radiation). Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.	Results	13
surgery	OAE:0000067	75-82
surgery	OAE:0000067	247-254
adjuvant	CHEBI:60809	126-134
radiotherapy	OAE:0000235	212-224
chemotherapy: Given within 10 weeks after surgery.	Results	14
surgery	OAE:0000067	42-49
Overall Number of Participants Analyzed: 85	Results	15
Measure Type: Number	Results	16
Unit of Measure: percentage of participants  69        (56 to 79)	Results	17
Adverse Events 1:	Adverse Events	0
Total: 0/77 (0.00%)	Adverse Events	1
Neutropenia  [1]0/77 (0.00%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	0-11
Left ventricular dysfunction 0/77 (0.00%)	Adverse Events	3
left	HP:0012835	0-4
Cardiac ischemia 0/77 (0.00%)	Adverse Events	4
ischemia	DOID:326	8-16
Gastrointestinal pain 0/77 (0.00%)	Adverse Events	5
pain	HP:0012531	17-21
Colitis 0/77 (0.00%)	Adverse Events	6
colitis	HP:0002583,DOID:0060180	0-7
Febrile neutropenia 0/77 (0.00%)	Adverse Events	7
neutropenia	HP:0001875,DOID:1227	8-19
Pulmonary/upper respiratory infection 0/77 (0.00%)	Adverse Events	8
Diverticulitis 0/77 (0.00%)	Adverse Events	9
diverticulitis	DOID:7475	0-14
Motor neuropathy 0/77 (0.00%)	Adverse Events	10
neuropathy	DOID:870	6-16
Endometrial mucosa thinkening 0/77 (0.00%)	Adverse Events	11
mucosa	UBERON:0000344	12-18
Adverse Events 2:	Adverse Events	12
Total: 12/85 (14.12%)	Adverse Events	13
Neutropenia  [1]1/85 (1.18%)	Adverse Events	14
neutropenia	HP:0001875,DOID:1227	0-11
Left ventricular dysfunction 1/85 (1.18%)	Adverse Events	15
left	HP:0012835	0-4
Cardiac ischemia 2/85 (2.35%)	Adverse Events	16
ischemia	DOID:326	8-16
Gastrointestinal pain 1/85 (1.18%)	Adverse Events	17
pain	HP:0012531	17-21
Colitis 1/85 (1.18%)	Adverse Events	18
colitis	HP:0002583,DOID:0060180	0-7
Febrile neutropenia 3/85 (3.53%)	Adverse Events	19
neutropenia	HP:0001875,DOID:1227	8-19
Pulmonary/upper respiratory infection 1/85 (1.18%)	Adverse Events	20
Diverticulitis 1/85 (1.18%)	Adverse Events	21
diverticulitis	DOID:7475	0-14
Motor neuropathy 1/85 (1.18%)	Adverse Events	22
neuropathy	DOID:870	6-16
Endometrial mucosa thinkening 1/85 (1.18%)	Adverse Events	23
mucosa	UBERON:0000344	12-18
